OBJECTIVE: To retrospectively review the charts of 13 @entity1 diagnosed with @entity5436 ( @entity5436 ) 2/3 treated with imiquimod and to evaluate the efficacy of this treatment. STUDY DESIGN: Retrospective review. All 13 @entity1 were treated and evaluated by a single gynecologist. The extent of the lesions prior to treatment and the extent and degree of improvement were documented. Biopsy confirmation of disease was obtained for each individual. Response to treatment was categorized as complete regression, at least 75% regression or not improved. RESULTS: The mean duration of treatment was 3.3 months, and follow-up after completion of therapy was 5.5 months. Eight of the 13 @entity1 had complete regression of the @entity5436 . Four @entity1 demonstrated 75% regression of disease, and in one @entity6 @entity1 no improvement was seen. In two @entity1 demonstrating 75% lesion regression, invasive @entity189 was found in the area of @entity66 . In one instance this was determined to be superficially invasive @entity957 (1 mm of invasion), and in the second an anal tag was found to have invasive @entity957 . CONCLUSION: Medical management of @entity5436 2/3 with imiquimod is worth considering. However, careful evaluation of the @entity1 must be carried out prior to the institution of therapy to exclude the presence of invasive @entity957 .

Treatment of XXXX 2/3 with imiquimod.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'woman', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of the vulva'] @entity5436 :: ('MESH:D019048', 'Disease') :: ['VIN', 'vulvar intraepithelial neoplasia']
@entity5436 :: (MESH:D019048,Disease) :: ['vulvar intraepithelial neoplasia']
